Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Too frequently the investigator will provide “scientific” reasons to justify precluding analgesics from experimental procedures that may involve more than momentary pain, often wi...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
DATE: February 27, 2019TIME: 8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
Second harmonic generation (SHG) is a biophysical method that sensitively measures real-time conformational change of biomolecules attached to membranes. SHG has recently been applied to dete...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
DATE: February 26, 2019TIME: 11:00am PST, 2:00pm EST Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Too frequently the investigator will provide “scientific” reasons to justify precluding analgesics from experimental procedures that may involve more than momentary pain, often wi...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
DATE: February 27, 2019TIME: 8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
Second harmonic generation (SHG) is a biophysical method that sensitively measures real-time conformational change of biomolecules attached to membranes. SHG has recently been applied to dete...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
DATE: February 26, 2019TIME: 11:00am PST, 2:00pm EST Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to...
DATE: February 26, 2019TIME: 9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Xenobiotic-induced cardiotoxicity is a major concern for both pharmaceuticals and chemicals in the marketplace. For drugs, "Thorough QT/corrected QT (QTc)" (TQT) studies are corners...
A collection of opinions, questions and other assorted thoughts about the intersection of these developing technologies and preclinical studies primarily focused on the early discovery (as op...
In biomedical research, data should be treated as first-class corporate assets--they were expensive to create, they are expensive to maintain, and they have future business value. The petabyt...
Digitalization has transformed virtually every industry, but it has been slow to gain traction within the preclinical phase of the drug development journey. Recent advances in digital vivariu...
Follow
